1. Volume 67, Issue 2, Pages 334-341 (February 2015)
Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer 
Evan Y. Yu, Robert H. Getzenberg, Christopher C. Coss, Marc M. Gittelman, Thomas Keane, Ronald Tutrone, Laurence Belkoff, Robert Given, Joel Bass, Franklin Chu, Michael Gambla, Franklin Gaylis, James Bailen, Michael L. Hancock, Jordan Smith, James T. Dalton, Mitchell S. Steiner 
European Urology 
Volume 67, Issue 2, Pages (February 2015)
DOI: /j.eururo
Copyright © 2014 European Association of Urology Terms and Conditions

2. Fig. 1
Consolidated Standards of Reporting Trials diagram describing the G clinical trial.
European Urology  , DOI: ( /j.eururo )
Copyright © 2014 European Association of Urology Terms and Conditions

3. Fig. 2
Measurements of total testosterone and prostate-specific antigen (PSA) during the course of the study in days. (A) Absolute total testosterone and (B) percentage PSA decline measurements in the intention-to-treat population throughout the course of the study.
European Urology  , DOI: ( /j.eururo )
Copyright © 2014 European Association of Urology Terms and Conditions

4. Fig. 3
Free testosterone (T) levels. (A) Median free T (nanograms per deciliter) and (B) the percentage of free T (free T/total T) over the course of the study in the intention-to-treat population.
European Urology  , DOI: ( /j.eururo )
Copyright © 2014 European Association of Urology Terms and Conditions

5. Fig. 4
Percentage of patients who experienced hot flashes while on treatment. The occurrence of hot flashes during the specified time periods between study visits are plotted as a percentage of the patients experiencing them.
European Urology  , DOI: ( /j.eururo )
Copyright © 2014 European Association of Urology Terms and Conditions

6. Fig. 5
The bone turnover biomarkers (A) c-terminal telopeptide (CTX) and (B) bone-specific alkaline phosphatase (BSAP) are presented as the percentage change from baseline to day 120. These values represent only the castrate population because the patients who did not reach castrate testosterone levels were discontinued on the study on day 60.
European Urology  , DOI: ( /j.eururo )
Copyright © 2014 European Association of Urology Terms and Conditions